Details

Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia : a worldwide cross-sectional study
ID Elshorbagy, Amany (Author), ID Grošelj, Urh (Author), et al.

.pdfPDF - Presentation file, Download (898,54 KB)
MD5: 8D4FDA56A89A7846500606B6B7C1FDD0
URLURL - Source URL, Visit https://www.sciencedirect.com/science/article/pii/S2213858724002213 This link opens in a new window

Abstract
Background Statins are the cornerstone treatment for patients with heterozygous familial hypercholesterolaemia but research suggests it could increase the risk of type 2 diabetes in the general population. A low prevalence of type 2 diabetes was reported in some familial hypercholesterolaemia cohorts, raising the question of whether these patients are protected against type 2 diabetes. Obesity is a well known risk factor for the development of type 2 diabetes. We aimed to investigate the associations of known key determinants of type 2 diabetes with its prevalence in people with heterozygous familial hypercholesterolaemia. Methods This worldwide cross-sectional study used individual-level data from the EAS FHSC registry and included adults older than 18 years with a clinical or genetic diagnosis of heterozygous familial hypercholesterolaemia who had data available on age, BMI, and diabetes status. Those with known or suspected homozygous familial hypercholesterolaemia and type 1 diabetes were excluded. The main outcome was prevalence of type 2 diabetes overall and by WHO region, and in relation to obesity (BMI ≥30∙0 kg/m$^2$) and lipid-lowering medication as predictors. The study population was divided into 12 risk categories based on age (tertiles), obesity, and receiving statins, and the risk of type 2 diabetes was investigated using logistic regression. Findings Among 46 683 adults with individual-level data in the FHSC registry, 24 784 with heterozygous familial hypercholesterolaemia were included in the analysis from 44 countries. 19 818 (80%) had a genetically confirmed diagnosis of heterozygous familial hypercholesterolaemia. Type 2 diabetes prevalence in the total population was 5·7% (1415 of 24 784), with 4·1% (817 of 19 818) in the genetically diagnosed cohort. Higher prevalence of type 2 diabetes was observed in the Eastern Mediterranean (58 [29·9%] of 194), South-East Asia and Western Pacific (214 [12·0%] of 1785), and the Americas (166 [8·5%] of 1955) than in Europe (excluding the Netherlands; 527 [8·0%] of 6579). Advancing age, a higher BMI category (obesity and overweight), and use of lipid-lowering medication were associated with a higher risk of type 2 diabetes, independent of sex and LDL cholesterol. Among the 12 risk categories, the probability of developing type 2 diabetes was higher in people in the highest risk category (aged 55–98 years, with obesity, and receiving statins; OR 74∙42 [95% CI 47∙04–117∙73]) than in those in the lowest risk category (aged 18–38 years, without obesity, and not receiving statins). Those who did not have obesity, even if they were in the upper age tertile and receiving statins, had lower risk of type 2 diabetes (OR 24∙42 [15∙57–38∙31]). The corresponding results in the genetically diagnosed cohort were OR 65∙04 (40∙67–104∙02) for those with obesity in the highest risk category and OR 20∙07 (12∙73–31∙65) for those without obesity. Interpretation Adults with heterozygous familial hypercholesterolaemia in most WHO regions have a higher type 2 diabetes prevalence than in Europe. Obesity markedly increases the risk of diabetes associated with age and use of statins in these patients. Our results suggest that heterozygous familial hypercholesterolaemia does not protect against type 2 diabetes, hence managing obesity is essential to reduce type 2 diabetes in this patient population.

Language:English
Keywords:type 2 diabetes mellitus, aged people, risk factors, cross-sectional studies
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2024
Number of pages:Str. 811-823
Numbering:Vol. 12, iss. 11
PID:20.500.12556/RUL-182441 This link opens in a new window
UDC:616.379
ISSN on article:2213-8587
DOI:10.1016/S2213-8587(24)00221-3 This link opens in a new window
COBISS.SI-ID:211828227 This link opens in a new window
Publication date in RUL:12.05.2026
Views:242
Downloads:259
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:The lancet. Diabetes & endocrinology
Publisher:Elsevier
ISSN:2213-8587
COBISS.SI-ID:1636780 This link opens in a new window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.

Secondary language

Language:Slovenian
Keywords:sladkorna bolezen tipa 2, starostniki, dejavniki tveganja, presečne študije

Projects

Funder:Pfizer
Project number:16157823

Funder:Amgen

Funder:MSD

Funder:Sanofi-Aventis

Funder:Daiichi-Sankyo

Funder:Regeneron

Funder:NIHR - National Institute for Health and Care Research
Funding programme:Applied Research Collaboration, Northwest London, PhD Studentship

Funder:NIHR - National Institute for Health and Care Research
Funding programme:Applied Research Collaboration, Northwest London

Funder:NIHR - National Institute for Health and Care Research
Funding programme:Imperial Biomedical Research Centre

Funder:Spain, Ministry of Universities
Funding programme:Beatriz Galindo

Funder:University of Seville

Funder:Ministry of Health
Funding programme:Ricerca Corrente

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back